Benzinga•2026-04-21
Rapport Therapeutics To Announce Results From Phase 2a Trial Of RAP-219 At American Academy Of Neurology Annual Meeting April 18-22RAPP — Rapport Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$36.95+22.07%Market cap1.38B
- Latest Close
- $36.95
- 30-Day Move
- +22.1%
- Market Cap
- $1.4B
- Shares Outstanding
- 47,790,000
- P/B Ratio
- 2.98
- ROE
- -23.0%
Analyst consensus: Buy · 16 analysts
NASDAQ:RAPPPharmaceuticals / PharmaceuticalsDelayed public snapshot
Rapport Therapeutics Inc
A read-only Alphactor snapshot forRapport Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$36.95
30-Day Move
+22.1%
Market Cap
$1.4B
Shares Outstanding
47,790,000
P/B Ratio
2.98
ROE
-23.0%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$36.95
+22.1%last 90 delayed daily bars
Market cap$1.4B
90D High
$40.92
90D Low
$25.21
Avg Volume
360,116
What stands out
RAPP is up 22.1% over the last 30 trading days shown on this page.
Latest operating income is $-125M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
78.7%
Fundamentals snapshot
Latest Close
$36.95
30-Day Move
+22.1%
Market Cap
$1.4B
Shares Outstanding
47,790,000
P/B Ratio
2.98
ROE
-23.0%
ROA
-21.8%
Debt / Equity
0
Current Ratio
26.17
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-125M
Net Income
$-111M
Gross Margin
--
Net Margin
--
Current Ratio
26.17
Debt / Equity
0.00
Quality snapshot
Altman Z
29.49
Safe
Piotroski
2
Weak (0-3)
Cash Conversion
0.78x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2023-12-31 | $0 | $-36M | $-35M | $-29M |
| 2024-12-31 | $0 | $-83M | $-78M | $-67M |
| 2025-12-31 | $0 | $-125M | $-111M | $-88M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-21
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual MeetingAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| SmallCap World Fund Inc | 3,123,982 | 0.07% | 2025-12-31 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1,995,667 | 0.04% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 973,330 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 691,813 | 0.01% | 2026-02-28 |
| T. Rowe Price Health Sciences Fund, Inc. | 643,434 | 0.01% | 2025-12-31 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 630,615 | 0.01% | 2026-02-28 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 526,534 | 0.01% | 2026-02-28 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 471,773 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-08-14
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$216M
+2.8%
Goldman Sachs
Filed 2026-02-10
$91M
+23.9%
Vanguard Group
Filed 2026-01-29
$55M
+11.8%
Geode Capital Management
Filed 2026-02-09
$21M
+30.2%
Invesco
Filed 2026-02-19
$8M
+69.1%
D.E. Shaw
Filed 2026-02-17
$8M
--
Charles Schwab
Filed 2026-02-13
$7M
+20.7%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.25
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
16
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.